SCHEMBL4553053

SCHEMBL4553053

CS(=O)(=O)c1cccc(C(O)(C(=O)c2ccccc2)S(C)(=O)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
GAA P10253 2/20 0.46
HSD17B10 Q99714 1/20 0.46
KIF11 P52732 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
ACSS2 Q9NR19 1/20 0.40
CES1 P23141 1/20 0.40
KAT6A Q92794 1/20 0.39
PTGS2 P35354 3/20 0.38
ACHE P22303 1/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.36
FAAH O00519 1/20 0.36
MGLL Q99685 1/20 0.36
SRC P12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3631032 0.85 CES1 (0.49) ALDH1A1SMN1; SMN2CES1SRC
SCHEMBL12157465 0.73 KIF11 (0.48) ALDH1A1GAAHSD17B10KIF11SMN1; SMN2
SCHEMBL29453108 0.71 ALDH1A1 (0.58) ALDH1A1GAAHSD17B10SMN1; SMN2AKR1C1
SCHEMBL28004 0.71 ALDH1A1 (0.58) ALDH1A1GAAHSD17B10SMN1; SMN2AKR1C1
SCHEMBL30628251 0.71 KIF11 (0.47) ALDH1A1GAAHSD17B10KIF11RXFP1
SCHEMBL17420495 0.71 KIF11 (0.47) ALDH1A1GAAHSD17B10KIF11RXFP1
SCHEMBL13543253 0.70 SMN1; SMN2 (0.51) ALDH1A1GAAHSD17B10SMN1; SMN2RXFP1
SCHEMBL11858816 0.70 KIF11 (0.52) ALDH1A1GAAHSD17B10KIF11ACSS2
Hydrochloric Acid SCHEMBL35358 0.70 ALDH1A1 (0.56) ALDH1A1GAAHSD17B10SMN1; SMN2AKR1C1
SCHEMBL826993 0.70 CES1 (0.46) ALDH1A1HSD17B10SMN1; SMN2CES1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605163-B2 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. (US) 2009-10-20 US disclosed
US-20080119486-A1 BENZOYL-PIPERAZINE DERIVATIVES JOLIDON SYNESE 2008-05-22 US disclosed
US-7319099-B2 Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-20050209241-A1 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209241-A1 Benzoyl-piperazine derivatives SLC1A2, SLC18A2, SLC6A7 ALDH1A1 1436/4885GAA 76/4885HSD17B10 2913/4885
US-20080119486-A1 BENZOYL-PIPERAZINE DERIVATIVES SLC1A2, SLC18A2, SLC6A7 ALDH1A1 1436/4885GAA 76/4885HSD17B10 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.